Lung Cancer Trial, Recruiting NCT06021483 Sponsor: Boryung Pharmaceutical Co., Ltd Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06021483
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given written consent to have their personal information collected and used for the study, after being informed about its purpose and methods
  • People who have already received, or are planned to receive, the medication Zepzelca™ injection, in line with its approved use
  • People who have small cell lung cancer (SCLC) that has spread to other parts of the body, and whose cancer did not respond to an initial chemotherapy treatment containing platinum-based drugs

Who may not be able to join:

  • People who have never previously received platinum-based chemotherapy as part of their cancer treatment
  • People who have had an allergic or sensitivity reaction to Zepzelca™ or any of its ingredients
  • Women who are pregnant, possibly pregnant, or currently breastfeeding
  • People who are currently taking part in another clinical trial involving a drug or medical device, or who plan to do so during the study period (note: participation in non-interventional studies, or trials where the drug phase has ended and only follow-up remains, may be acceptable — confirm with trial site)
  • People whom the lead or supporting study doctor considers unsuitable to participate for any reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +82-2-708-8000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Boryung Pharmaceutical Co., Ltd
Registry
ClinicalTrials.gov
Start date
16 August 2023
Est. completion
1 September 2025

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

ORR (Overall Response Rate)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov